SutroVax is a recently established company developing best-in-class conjugate vaccines and complex antigen-based vaccines for infectious diseases. The company's lead programme is a broad-spectrum pneumococcal conjugate vaccine in preclinical trials. SutroVax has an exclusive license to Sutro Biopharma’s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation.

Location South San Francisco, California
CEO Grant Pickering
Partner Kurt von Emster